{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T14:02:52Z","timestamp":1775829772845,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:00:00Z","timestamp":1559088000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:00:00Z","timestamp":1559088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["171339, 171339 and 171339"],"award-info":[{"award-number":["171339, 171339 and 171339"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001922","name":"Efficacy and Mechanism Evaluation Programme","doi-asserted-by":"publisher","award":["11\/100\/50"],"award-info":[{"award-number":["11\/100\/50"]}],"id":[{"id":"10.13039\/501100001922","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["A13363 and 162082"],"award-info":[{"award-number":["A13363 and 162082"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009010","name":"Novartis Pharmaceuticals UK Limited","doi-asserted-by":"crossref","award":["158519"],"award-info":[{"award-number":["158519"]}],"id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","award":["163301"],"award-info":[{"award-number":["163301"]}],"id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","award":["163026"],"award-info":[{"award-number":["163026"]}],"id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AstraZeneca","award":["158046"],"award-info":[{"award-number":["158046"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13063-019-3216-8","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T23:04:10Z","timestamp":1559084650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols"],"prefix":"10.1186","volume":"20","author":[{"name":"On behalf of past and present members of the STAMPEDE and FOCUS4 Trial Management Group","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8253-9581","authenticated-orcid":false,"given":"Francesca","family":"Schiavone","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1963-3831","authenticated-orcid":false,"given":"Riya","family":"Bathia","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7886-4779","authenticated-orcid":false,"given":"Krishna","family":"Letchemanan","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1587-8065","authenticated-orcid":false,"given":"Lindsey","family":"Masters","sequence":"additional","affiliation":[]},{"given":"Claire","family":"Amos","sequence":"additional","affiliation":[]},{"given":"Anna","family":"Bara","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2827-6634","authenticated-orcid":false,"given":"Louise","family":"Brown","sequence":"additional","affiliation":[]},{"given":"Clare","family":"Gilson","sequence":"additional","affiliation":[]},{"given":"Cheryl","family":"Pugh","sequence":"additional","affiliation":[]},{"given":"Nafisah","family":"Atako","sequence":"additional","affiliation":[]},{"given":"Fleur","family":"Hudson","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0166-1700","authenticated-orcid":false,"given":"Mahesh","family":"Parmar","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9706-016X","authenticated-orcid":false,"given":"Ruth","family":"Langley","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0189-8348","authenticated-orcid":false,"given":"Richard S.","family":"Kaplan","sequence":"additional","affiliation":[]},{"given":"Chris","family":"Parker","sequence":"additional","affiliation":[]},{"given":"Gert","family":"Attard","sequence":"additional","affiliation":[]},{"given":"Noel W.","family":"Clarke","sequence":"additional","affiliation":[]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7314-8204","authenticated-orcid":false,"given":"Nicholas D.","family":"James","sequence":"additional","affiliation":[]},{"given":"Tim","family":"Maughan","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9323-1371","authenticated-orcid":false,"given":"Matthew R.","family":"Sydes","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,5,29]]},"reference":[{"issue":"3","key":"3216_CR1","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1177\/1740774515626362","volume":"13","author":"BR Saville","year":"2016","unstructured":"Saville BR, Berry SM. Efficiencies of platform clinical trials: A vision of the future. Clin Trials. 2016;13(3):358\u201366.","journal-title":"Clin Trials"},{"issue":"1","key":"3216_CR2","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13063-016-1273-9","volume":"17","author":"I Hatfield","year":"2016","unstructured":"Hatfield I, Allison A, Flight L, Julious SA, Dimairo M. Adaptive designs undertaken in clinical research: a review of registered clinical trials. Trials. 2016;17(1):150.","journal-title":"Trials"},{"issue":"2","key":"3216_CR3","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1177\/0962280212465498","volume":"25","author":"J Wason","year":"2016","unstructured":"Wason J, Magirr D, Law M, Jaki T. Some recommendations for multi-arm multi-stage trials. Stat Methods Med Res. 2016;25(2):716\u201327.","journal-title":"Stat Methods Med Res"},{"key":"3216_CR4","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/1745-6215-13-168","volume":"13","author":"MR Sydes","year":"2012","unstructured":"Sydes MR, Parmar MK, Mason MD, Clarke NW, Amos C, Anderson J, et al. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials. 2012;13:168.","journal-title":"Trials"},{"issue":"5","key":"3216_CR5","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1177\/1740774517725697","volume":"14","author":"MK Parmar","year":"2017","unstructured":"Parmar MK, Sydes MR, Cafferty FH, Choodari-Oskooei B, Langley RE, Brown L, et al. Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols. Clin Trials. 2017;14(5):451\u201361.","journal-title":"Clin Trials"},{"issue":"9940","key":"3216_CR6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(14)61122-3","volume":"384","author":"MK Parmar","year":"2014","unstructured":"Parmar MK, Carpenter J, Sydes MR. More multiarm randomised trials of superiority are needed. Lancet. 2014;384(9940):283\u20134.","journal-title":"Lancet"},{"issue":"1","key":"3216_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMra1510062","volume":"377","author":"J Woodcock","year":"2017","unstructured":"Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med. 2017;377(1):62\u201370.","journal-title":"N Engl J Med"},{"issue":"3","key":"3216_CR8","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1177\/1740774516688900","volume":"14","author":"SC Mawocha","year":"2017","unstructured":"Mawocha SC, Fetters MD, Legocki LJ, Guetterman TC, Frederiksen S, Barsan WG, et al. A conceptual model for the development process of confirmatory adaptive clinical trials within an emergency research network. Clin Trials. 2017;14(3):246\u201354.","journal-title":"Clin Trials"},{"issue":"3","key":"3216_CR9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S2468-1253(17)30394-1","volume":"3","author":"R Adams","year":"2018","unstructured":"Adams R, Brown E, Brown L, Butler R, Falk S, Fisher D, et al. Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2\u20133 randomised trial. Lancet Gastroenterol Hepatol. 2018;3(3):162\u201371.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3216_CR10","doi-asserted-by":"crossref","unstructured":"A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet. 2005;365(9460):711\u201322.","DOI":"10.1016\/S0140-6736(05)70939-9"},{"key":"3216_CR11","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1186\/1745-6215-15-464","volume":"15","author":"VC Brueton","year":"2014","unstructured":"Brueton VC, Vale CL, Choodari-Oskooei B, Jinks R, Tierney JF. Measuring the impact of methodological research: a framework and methods to identify evidence of impact. Trials. 2014;15:464.","journal-title":"Trials"},{"issue":"1","key":"3216_CR12","doi-asserted-by":"publisher","first-page":"A6","DOI":"10.1186\/1745-6215-12-S1-A6","volume":"12","author":"J Hearn","year":"2011","unstructured":"Hearn J, Keat N, Law K, Sharpe R. How Cancer Research UK is adapting to adaptive designs. Trials. 2011;12(1):A6.","journal-title":"Trials"},{"issue":"1","key":"3216_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1136\/jclinpath-2015-203097","volume":"69","author":"SD Richman","year":"2016","unstructured":"Richman SD, Adams R, Quirke P, Butler R, Hemmings G, Chambers P, et al. Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial. J Clin Pathol. 2016;69(1):35\u201341.","journal-title":"J Clin Pathol"},{"issue":"3","key":"3216_CR14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200\u20137.","journal-title":"Ann Intern Med"},{"key":"3216_CR15","doi-asserted-by":"crossref","unstructured":"Parker CC, Sydes MR, Mason MD, Clarke NW, Aebersold D, de Bono JS, et al. Prostate radiotherapy for men with metastatic disease: a new comparison in the STAMPEDE Trial. Clin Oncol. 25(5):318\u201320.","DOI":"10.1016\/j.clon.2013.01.005"},{"issue":"5","key":"3216_CR16","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.eururo.2014.05.038","volume":"66","author":"G Attard","year":"2014","unstructured":"Attard G, Sydes MR, Mason MD, Clarke NW, Aebersold D, de Bono JS, et al. Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE Trial. Eur Urol. 2014;66(5):799\u2013802.","journal-title":"Eur Urol"},{"key":"3216_CR17","doi-asserted-by":"crossref","unstructured":"Gillessen S, Gilson C, James N, Adler A, Sydes MR, Clarke N. Repurposing metformin as therapy for prostate cancer within the STAMPEDE Trial platform. Eur Urol. 70(6):906\u20138.","DOI":"10.1016\/j.eururo.2016.07.015"},{"key":"3216_CR18","doi-asserted-by":"crossref","unstructured":"Gilbert DC, Duong T, Sydes M, Bara A, Clarke N, Abel P, et al. Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform. BJU Int. 2018.","DOI":"10.1111\/bju.14153"},{"issue":"10024","key":"3216_CR19","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163\u201377.","journal-title":"Lancet"},{"issue":"2","key":"3216_CR20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","volume":"17","author":"CL Vale","year":"2016","unstructured":"Vale CL, Burdett S, Rydzewska LHM, Albiges L, Clarke NW, Fisher D, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 2016;17(2):243\u201356.","journal-title":"Lancet Oncol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3216-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-019-3216-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3216-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T23:16:37Z","timestamp":1590621397000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-019-3216-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,29]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3216"],"URL":"https:\/\/doi.org\/10.1186\/s13063-019-3216-8","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,29]]},"assertion":[{"value":"10 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The FOCUS4 and STAMPEDE trials have received favourable opinion by the relevant Research Ethics Committee (13\/SC\/0111 and 04\/MRE07\/35).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"264"}}